Welcome to the DZIF -
the German Center for Infection Research

Community-Acquired Infections at Mucosal Interfaces

Hepatitis

HIV

Infections of the Immunocompromised Host

Healthcare-Associated Infections

Malaria and Neglected Tropical Diseases

Emerging Infections

Novel Antibiotics

Tuberculosis

Red-coloured rod-shaped bacteria in an electron micrograph.

Jan 8 2025

Tuberculosis research: promising new active agent

Jan 6 2025

Horizon Europe project DEFENDER: New targets for antiviral therapies

The interdisciplinary project DEFENDER is developing innovative approaches to combat (re-)emerging viruses. The project, coordinated by the Leibniz Institute of Virology (LIV), is being funded with

Members of the round table dialogue, from left: Georg Kippels (MdB), Thomas Müller (BMG), Helge Braun (MdB), Marc Gitzinger (BEAM Alliance), Thomas Hälbig (GKV-Spitzenverband), and Timo Jäger (DZIF)

Dec 18 2024

Second working meeting of the Parliamentary Group against Antimicrobial Resistance

(AMR) is one of the greatest challenges for global health and development. According to estimates by the World Health Organisation (WHO), almost five million deaths worldwide

Dec 16 2024

Start-up EBViously founded

EBViously, a spin-off of Helmholtz Munich, officially started operations on 11 November 2024. The company is developing a preventive against diseases caused by the (EBV)

Three agar plates with Streptomyces colonies in different colours (reddish, blue, orange).

Dec 13 2024

Activating the hidden pharmaceutical potential of bacteria

Microorganisms produce a wide variety of natural products that can be used as active agents to treat diseases such as infections or cancer. The blueprints for these molecules can be found in the

All news

The DZIF team wishes everyone:

A happy new year!

Here's to a year 2025 full of exciting discoveries, new ways of diagnosing and treating infectious diseases, and health and peace for every single person in the world!

Cut-out from the cover of the 2022 annual report

pdf (3.36 MB)

Das zentrale Bioprobenregister im DZIF

Video

pdf (3.65 MB)

DZIF Annual Report 2021

pdf (3.65 MB)

Find Media Content

Hamburg - Lübeck - Borstel - Riems

The Clinical Tuberculosis Centre provides the expertise and infrastructure for the optimisation, prevention, diagnosis and treatment of tuberculosis (TB) as well as for translating research results into clinical practice. The main objectives of the Clinical Tuberculosis Centre include coordinating clinical research activities involving the DZIF TB cohort. This cohort includes [...]

Hannover - Braunschweig | Heidelberg | München | Tübingen

Transplant Cohort

Medical data and biological samples obtained from transplant patients are collected and managed across Germany with the help of the DZIF Transplant Cohort. The data and samples form the basis of scientific studies which investigate the connections between numerous factors influencing an organ’s susceptibility to infection and organ function. In [...]

Tübingen

New strategies for specific eradication of Staphylococcus aureus

In this project, the scientists develop genetically engineered phage lysins and specific bacteriocins for the elimination of hospital germs such as Staphylococcus aureus, they clarify mechanisms of potential resistance mechanisms, and they analyse whether broad-spectrum or specifically acting agents have a more effective and lasting effect on colonization by [...]

Hannover - Braunschweig

Preclinical development of Amidochelocardins

The challenge of antibiotic drug development today is the discovery and optimisation of novel bioactive compounds that do not show cross-resistances with clinically applied antibiotics, ideally due to a novel mode of action (MoA) which adresses unexploited microbial targets. In the case of chelocardin, this antibiotic substance was identified several [...]